Cargando…

TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis

Myelofibrosis (MF) is a progressive chronic myeloproliferative neoplasm characterized by hyperactivation of JAK/STAT signaling and dysregulation of the transcription factor GATA1 in megakaryocytes (MKs). TGF-β plays a pivotal role in the pathobiology of MF by promoting BM fibrosis and collagen depos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varricchio, Lilian, Iancu-Rubin, Camelia, Upadhyaya, Bhaskar, Zingariello, Maria, Martelli, Fabrizio, Verachi, Paola, Clementelli, Cara, Denis, Jean-Francois, Rahman, Adeeb H., Tremblay, Gilles, Mascarenhas, John, Mesa, Ruben A., O’Connor-McCourt, Maureen, Migliaccio, Anna Rita, Hoffman, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492354/ https://www.ncbi.nlm.nih.gov/pubmed/34383713 http://dx.doi.org/10.1172/jci.insight.145651

Ejemplares similares

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Resident Self-Tissue of Proinflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Gata1(low) Mice
por: Zingariello, Maria, et al.
Publicado: (2022)

Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells
por: Lu, Min, et al.
Publicado: (2021)

The thrombopoietin/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature
por: Zingariello, M, et al.
Publicado: (2017)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology
por: Eran, Zimran, et al.
Publicado: (2019)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Single cell analysis of the localization of the hematopoietic stem cells within the bone marrow architecture identifies niche-specific proliferation dynamics
por: Mazzarini, Maria, et al.
Publicado: (2023)

hGATA1 Under the Control of a μLCR/β-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1 ( low ) Mutation in Mice
por: Martelli, Fabrizio, et al.
Publicado: (2021)

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 (low) Mice
por: Verachi, Paola, et al.
Publicado: (2022)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
por: Zingariello, Maria, et al.
Publicado: (2020)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Role of β1 integrin in thrombocytopoiesis
por: Mazzarini, Maria, et al.
Publicado: (2021)

A case of perirenal extramedullary hematopoiesis in a patient with primary myelofibrosis
por: Imai, Kentaro, et al.
Publicado: (2017)

Extramedullary hematopoiesis in an inguinal lymph node: an unusual presentation of primary myelofibrosis
por: Yaqoob, Nausheen, et al.
Publicado: (2022)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients
por: Ojeda‐Uribe, Mario, et al.
Publicado: (2016)

Generalized lymphadenopathy secondary to isolated extramedullary hematopoiesis as an initial manifestation of primary myelofibrosis
por: Aljabry, Mansour S., et al.
Publicado: (2018)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis
por: Varricchio, Lilian, et al.
Publicado: (2022)

CT findings of extramedullary hematopoiesis in the thorax, liver and kidneys, in a patient with idiopathic myelofibrosis.
por: Kwak, H. S., et al.
Publicado: (2000)

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis
por: Barraco, D, et al.
Publicado: (2016)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis
por: Casaccia, Marco, et al.
Publicado: (2017)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

Chronic Idiopathic Myelofibrosis Presenting as Cauda Equina Compression due to Extramedullary Hematopoiesis: A Case Report
por: Goh, Duck-Ho, et al.
Publicado: (2007)

Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

A 54-year-old Woman with Myelofibrosis and Massive Hemothorax Due to Primary Extramedullary Hematopoiesis of the Pleura
por: Karass, Michael, et al.
Publicado: (2018)

Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets
por: Psaila, Bethan, et al.
Publicado: (2020)

Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
por: Naymagon, Leonard, et al.
Publicado: (2017)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

A Case Report on Hepatic Extramedullary Hematopoiesis as the Manifestation of Progression to Secondary Myelofibrosis in a Patient with Essential Thrombocytopenia
por: McArthur, Kaitlin I., et al.
Publicado: (2022)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
por: Gleitz, Hélène, et al.
Publicado: (2023)

Emerging Treatment Options for Myelofibrosis: Focus on Anemia
por: Sastow, Dahniel, et al.
Publicado: (2023)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
por: Gobbo, Francesca, et al.
Publicado: (2023)

The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis
por: Liu, Lulu, et al.
Publicado: (2018)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3hhbnvd05trl5scpkmd9ritg43